Anurag Mantri appointed as President of Glenmark Pharmaceuticals

Mantri will replace V. S. Mani, Executive Director & Global Chief Financial Officer of the company as he has conveyed his decision to opt for early retirement

Cosmo and Glenmark receives UK MHRA approval to market Winlevi in UK

Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations

Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr

India Business grew by 11.9% YoY to Rs. 1196.2 crore

Glenmark to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 diabetes

Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually

Glenmark Pharma to sell 75% stake in Glenmark Life Sciences to Nirma for Rs. 5,652 Cr

Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Hydrochloride Capsules USP

Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million

USFDA provides exception to Glenmark's Baddi facility

The company will engage with the agency to resolve the import alert at the earliest.

Briefs: J. B. Chemicals & Pharmaceuticals, Dr. Reddy’s Laboratories and Piramal Enterprises

J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.

Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes

This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation